218 related articles for article (PubMed ID: 16309172)
1. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.
Wehbe H; Kearney CM; Pinney KG
Anticancer Res; 2005; 25(6B):3865-70. PubMed ID: 16309172
[TBL] [Abstract][Full Text] [Related]
2. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
Gan PP; Kavallaris M
Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
[TBL] [Abstract][Full Text] [Related]
3. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
4. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
Gan PP; Pasquier E; Kavallaris M
Cancer Res; 2007 Oct; 67(19):9356-63. PubMed ID: 17909044
[TBL] [Abstract][Full Text] [Related]
5. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
Ranganathan S; McCauley RA; Dexter DW; Hudes GR
Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells.
Banerjee A
Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644
[TBL] [Abstract][Full Text] [Related]
7. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
Verdier-Pinard P; Wang F; Martello L; Burd B; Orr GA; Horwitz SB
Biochemistry; 2003 May; 42(18):5349-57. PubMed ID: 12731876
[TBL] [Abstract][Full Text] [Related]
8. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
9. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
10. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells.
Vitale I; Antoccia A; Cenciarelli C; Crateri P; Meschini S; Arancia G; Pisano C; Tanzarella C
Apoptosis; 2007 Jan; 12(1):155-66. PubMed ID: 17143747
[TBL] [Abstract][Full Text] [Related]
11. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).
Dumontet C; Duran GE; Steger KA; Beketic-Oreskovic L; Sikic BI
Cancer Res; 1996 Mar; 56(5):1091-7. PubMed ID: 8640766
[TBL] [Abstract][Full Text] [Related]
12. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells.
Yoshida M; Matsui Y; Ikarashi Y; Usui T; Osada H; Wakasugi H
Anticancer Res; 2007; 27(2):729-36. PubMed ID: 17465195
[TBL] [Abstract][Full Text] [Related]
15. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
16. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines.
Hiser L; Aggarwal A; Young R; Frankfurter A; Spano A; Correia JJ; Lobert S
Cell Motil Cytoskeleton; 2006 Jan; 63(1):41-52. PubMed ID: 16362954
[TBL] [Abstract][Full Text] [Related]
17. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
18. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
Zhou J; Cheng SC; Luo D; Xie Y
Biochem Biophys Res Commun; 2001 Feb; 280(5):1237-42. PubMed ID: 11162660
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
Isonishi S; Saitou M; Saitou M; Yasuda M; Tanaka T
Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368
[TBL] [Abstract][Full Text] [Related]
20. Biochemical genetic analysis of indanocine resistance in human leukemia.
Hua XH; Genini D; Gussio R; Tawatao R; Shih H; Kipps TJ; Carson DA; Leoni LM
Cancer Res; 2001 Oct; 61(19):7248-54. PubMed ID: 11585762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
